137 related articles for article (PubMed ID: 10693700)
1. Overexpression of Fas-ligand by neuroblastoma: a novel mechanism of tumor-cell killing.
Takamizawa S; Okamoto S; Wen J; Bishop W; Kimura K; Sandler A
J Pediatr Surg; 2000 Feb; 35(2):375-9. PubMed ID: 10693700
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
Shurin GV; Gerein V; Lotze MT; Barksdale EM
Nat Immun; 1998; 16(5-6):263-74. PubMed ID: 11061594
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the mouse Fas gene in human Hep3B hepatoma cells overcomes their resistance to Fas-mediated apoptosis.
Lamboley C; Bringuier AF; Camus E; Lardeux B; Groyer A; Feldmann G
J Hepatol; 2002 Mar; 36(3):385-94. PubMed ID: 11867183
[TBL] [Abstract][Full Text] [Related]
5. Fas expression prevents cholangiocarcinoma tumor growth.
Pickens A; Pan G; McDonald JM; Vickers SM
J Gastrointest Surg; 1999; 3(4):374-81; discussion 382. PubMed ID: 10482689
[TBL] [Abstract][Full Text] [Related]
6. Fas-mediated induction of hepatocyte apoptosis in a neuroblastoma and hepatocyte coculture model.
Chen MK; Strande LF; Beierle EA; Kain MS; Geldziler BD; Doolin EJ
J Surg Res; 1999 Jun; 84(1):82-7. PubMed ID: 10334894
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
9. The survivin:Fas ratio is predictive of recurrent disease in neuroblastoma.
Sandler A; Scott D; Azuhata T; Takamizawa S; O'Dorisio S
J Pediatr Surg; 2002 Mar; 37(3):507-11. PubMed ID: 11877677
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
[TBL] [Abstract][Full Text] [Related]
11. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
12. Zeta-associated protein of 70 kDa (ZAP-70), but not Syk, tyrosine kinase can mediate apoptosis of T cells through the Fas/Fas ligand, caspase-8 and caspase-3 pathways.
Zhong L; Wu CH; Lee WH; Liu CP
J Immunol; 2004 Feb; 172(3):1472-82. PubMed ID: 14734724
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand is frequently expressed in human pancreatic duct cell carcinoma.
Satoh K; Shimosegawa T; Masamune A; Hirota M; Koizumi M; Toyota T
Pancreas; 1999 Nov; 19(4):339-45. PubMed ID: 10547193
[TBL] [Abstract][Full Text] [Related]
15. Silencing of the caspase-1 gene occurs in murine and human renal cancer cells and causes solid tumor growth in vivo.
Ueki T; Takeuchi T; Nishimatsu H; Kajiwara T; Moriyama N; Narita Y; Kawabe K; Ueki K; Kitamura T
Int J Cancer; 2001 Mar; 91(5):673-9. PubMed ID: 11267979
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fas ligand is not a main mechanism used by tumors to counteract antitumor immunity.
Chen CM; Song W; Kao JY; Zheng QD; Chen JJ
Front Biosci; 2004 Jan; 9():448-56. PubMed ID: 14766381
[TBL] [Abstract][Full Text] [Related]
17. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
18. Partial tolerance of subcutaneously transplanted xenogeneic tumour cell graft by Fas-mediated immunosuppression.
Sawada T; Koji T; Hishikawa Y; Kishimoto K; Nagayasu T; Takahashi T; Oka T; Ayabe H
Immunology; 2001 May; 103(1):81-9. PubMed ID: 11380695
[TBL] [Abstract][Full Text] [Related]
19. Role of Fas and granule exocytosis pathways in tumor-infiltrating T lymphocyte-induced apoptosis of autologous human lung-carcinoma cells.
Dorothee G; Ameyar M; Bettaieb A; Vergnon I; Echchakir H; Bouziane M; Chouaib S; Mami-Chouaib F
Int J Cancer; 2001 Mar; 91(6):772-7. PubMed ID: 11275978
[TBL] [Abstract][Full Text] [Related]
20. [Blocking the escape of leukemic cells from killing of T cell by combining anti-Fas ribozyme and CD80-IgG fusion protein].
Liu LB; Li WM; He W; Zhang M; Xiao J; Zhong ZD; Li L; Zou P
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3469-74. PubMed ID: 16686062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
